Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
Status:
Completed
Trial end date:
2005-04-15
Target enrollment:
Participant gender:
Summary
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as
measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic
impairment and in healthy subjects following a single oral inhaled dose of GW685698X. From
the study results it should be possible to assess if there is an altered Risk: Benefit in
patients with moderate hepatic impairment